Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Low interventional, open and multicentric clinical trial to evaluate the effect of alirocumab on volume, architecture and composition of atheroma plaque in patients with familial hypercholesterolemia from SAFEHEART registry. ARCHITECT study

Next Previous
Trial Profile

Low interventional, open and multicentric clinical trial to evaluate the effect of alirocumab on volume, architecture and composition of atheroma plaque in patients with familial hypercholesterolemia from SAFEHEART registry. ARCHITECT study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hyperlipoproteinaemia; Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Acronyms ARCHITECT

Most Recent Events

  • 29 Aug 2022 Primary endpoint has been met (Change in percent of atheroma volume of the coronary tree between baseline (before the initiation of alirocumab) and 18 months after the beginning of alirocumab, based on angio CT images, analyzed with QAngio TC software) , according to Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
  • 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
  • 15 Jun 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top